Works matching IS 01676997 AND DT 2019 AND VI 37 AND IP 3

Results: 24

Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer.

Published in:

Investigational New Drugs, 2019, v. 37, n. 3, p. 559, doi. 10.1007/s10637-019-00778-4

By:

Koshkin, Vadim S.;
Mir, Maria C.;
Barata, Pedro;
Gul, Anita;
Gupta, Ruby;
Stephenson, Andrew J.;
Kaouk, Jihad;
Berglund, Ryan;
Magi-Galluzzi, Cristina;
Klein, Eric A.;
Dreicer, Robert;
Garcia, Jorge A.

Publication type:

Article

Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial.

Published in:

2019

By:

Inoue, Kenichi;
Ninomiya, Jun;
Saito, Tsuyoshi;
Okubo, Katsuhiko;
Nakakuma, Takashi;
Yamada, Hirofumi;
Kimizuka, Kei;
Higuchi, Tohru

Publication type:

Correction Notice

The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma.

Published in:

Investigational New Drugs, 2019, v. 37, n. 3, p. 548, doi. 10.1007/s10637-019-00769-5

By:

Cox, M. Christina;
Pelliccia, Sabrina;
Marcheselli, Luigi;
Battistini, Roberta;
Arcari, Annalisa;
Borza, Paola Anticoli;
Patti, Caterina;
Casaroli, Ivana;
di Landro, Francesca;
Di Napoli, Arianna;
Fabbri, Francesca;
Caridi, Matteo;
Tafuri, Agostino;
Bocci, Guido;
Musuraca, Gerardo

Publication type:

Article

Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor.

Published in:

2019

By:

Ito, Tetsuhide;
Okusaka, Takuji;
Nishida, Toshirou;
Yamao, Kenji;
Igarashi, Hisato;
Morizane, Chigusa;
Kondo, Shunsuke;
Mizuno, Nobumasa;
Hara, Kazuo;
Sawaki, Akira;
Hashigaki, Satoshi;
Kimura, Nobuyuki;
Murakami, Mami;
Ohki, Emiko;
Chao, Richard C.;
Imamura, Masayuki

Publication type:

Correction Notice

Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial.

Published in:

Investigational New Drugs, 2019, v. 37, n. 3, p. 538, doi. 10.1007/s10637-019-00755-x

By:

Inoue, Kenichi;
Ninomiya, Jun;
Saito, Tsuyoshi;
Okubo, Katsuhiko;
Nakakuma, Takashi;
Yamada, Hirofumi;
Kimizuka, Kei;
Higuchi, Tohru

Publication type:

Article

Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma.

Published in:

Investigational New Drugs, 2019, v. 37, n. 3, p. 531, doi. 10.1007/s10637-019-00747-x

By:

Akiyama, Norimichi;
Karayama, Masato;
Inui, Naoki;
Yasui, Hideki;
Hozumi, Hironao;
Suzuki, Yuzo;
Furuhashi, Kazuki;
Fujisawa, Tomoyuki;
Enomoto, Noriyuki;
Nakamura, Yutaro;
Inami, Nao;
Matsuura, Shun;
Kaida, Yusuke;
Uto, Tomohiro;
Matsui, Takashi;
Asada, Kazuhiro;
Matsuda, Hiroyuki;
Fujii, Masato;
Toyoshima, Mikio;
Suda, Takafumi

Publication type:

Article

The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer.

Published in:

Investigational New Drugs, 2019, v. 37, n. 3, p. 524, doi. 10.1007/s10637-019-00725-3

By:

Roviello, Giandomenico;
Petrioli, Roberto;
Rosellini, Pietro;
Multari, Andrea Giovanni;
Conca, Raffaele;
Paganini, Giovanni;
Chiriacò, Giorgio;
Aieta, Michele

Publication type:

Article

Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma.

Published in:

Investigational New Drugs, 2019, v. 37, n. 3, p. 567, doi. 10.1007/s10637-018-0707-5

By:

Yoo, Changhoon;
Park, Joong-Won;
Kim, Yoon Jun;
Kim, Do Young;
Yu, Su Jong;
Lim, Tae Seop;
Lee, Su Jin;
Ryoo, Baek-Yeol;
Lim, Ho Yeong

Publication type:

Article

Increasing complexity in oncology phase I clinical trials.

Published in:

Investigational New Drugs, 2019, v. 37, n. 3, p. 519, doi. 10.1007/s10637-018-0699-1

By:

Malik, Laeeq;
Lu, David

Publication type:

Article

First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2019, v. 37, n. 3, p. 507, doi. 10.1007/s10637-018-0697-3

By:

Doi, Toshihiko;
Yoh, Kiyotaka;
Shitara, Kohei;
Takahashi, Hideaki;
Ueno, Makoto;
Kobayashi, Satoshi;
Morimoto, Manabu;
Okusaka, Takuji;
Ueno, Hideki;
Morizane, Chigusa;
Okano, Naohiro;
Nagashima, Fumio;
Furuse, Junji

Publication type:

Article

Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.

Published in:

Investigational New Drugs, 2019, v. 37, n. 3, p. 584, doi. 10.1007/s10637-018-0681-y

By:

Hwang, Inhwan;
Kang, Jihoon;
Ip, Hei Nga Natalie;
Jeong, Jae Ho;
Kim, Kyu-pyo;
Chang, Heung-Moon;
Yoo, Changhoon;
Ryoo, Baek-Yeol

Publication type:

Article

Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens.

Published in:

Investigational New Drugs, 2019, v. 37, n. 3, p. 498, doi. 10.1007/s10637-018-0680-z

By:

Goffin, J. R.;
Nicholas, G.;
Mates, M.;
Tu, D.;
Chen, E.;
Laurie, S. A.;
Juergens, R.;
Robinson, A.;
Goss, G.;
Reaume, M.;
Sun, S.;
Christink, K.;
Maize, C.;
MacFarlan, S.;
Sun, X.;
Ritter, H.;
Seymour, L.;
Bradbury, P. A.

Publication type:

Article

Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer.

Published in:

Investigational New Drugs, 2019, v. 37, n. 3, p. 473, doi. 10.1007/s10637-018-0676-8

By:

Mahipal, Amit;
Tella, Sri Harsha;
Kommalapati, Anuhya;
Goyal, Gaurav;
Soares, Heloisa;
Neuger, Anthony;
Copolla, Domenico;
Kim, Jongphil;
Kim, Richard

Publication type:

Article

Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trials.

Published in:

Investigational New Drugs, 2019, v. 37, n. 3, p. 490, doi. 10.1007/s10637-018-0675-9

By:

Kam, Audrey E.;
Pendurti, Gopichand;
Shah, Umang H.;
Ghalib, Mohammad H.;
Chaudhary, Imran;
Chuy, Jennifer;
Rajdev, Lakshmi;
Kaubisch, Andreas;
Aparo, Santiago;
Mantzaris, Ioannis;
Goel, Sanjay

Publication type:

Article

Safety and efficacy of immune checkpoint inhibitors for end-stage renal disease patients undergoing dialysis: a retrospective case series and literature review.

Published in:

Investigational New Drugs, 2019, v. 37, n. 3, p. 579, doi. 10.1007/s10637-018-0673-y

By:

Cheun, Hyeon;
Kim, Miso;
Lee, Hajeong;
Oh, Kook-Hwan;
Keam, Bhumsuk

Publication type:

Article

Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study.

Published in:

Investigational New Drugs, 2019, v. 37, n. 3, p. 573, doi. 10.1007/s10637-018-0669-7

By:

Ida, Hanae;
Honma, Yoshitaka;
Hirano, Hidekazu;
Shoji, Hirokazu;
Iwasa, Satoru;
Okita, Natsuko;
Takashima, Atsuo;
Kato, Ken;
Fukuda, Takahiro;
Boku, Narikazu

Publication type:

Article

A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors.

Published in:

Investigational New Drugs, 2019, v. 37, n. 3, p. 461, doi. 10.1007/s10637-018-0665-y

By:

Jimeno, Antonio;
Moore, Kathleen N.;
Gordon, Michael;
Chugh, Rashmi;
Diamond, Jennifer R.;
Aljumaily, Raid;
Mendelson, David;
Kapoun, Ann M.;
Xu, Lu;
Stagg, Robert;
Smith, David C.

Publication type:

Article

HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.

Published in:

Investigational New Drugs, 2019, v. 37, n. 3, p. 441, doi. 10.1007/s10637-018-0649-y

By:

Canonici, Alexandra;
Ivers, Laura;
Conlon, Neil T.;
Pedersen, Kasper;
Gaynor, Nicola;
Browne, Brigid C.;
O'Brien, Neil A.;
Gullo, Giuseppe;
Collins, Denis M.;
O'Donovan, Norma;
Crown, John

Publication type:

Article

Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first–line treatment of metastatic colorectal cancer.

Published in:

Investigational New Drugs, 2019, v. 37, n. 3, p. 482, doi. 10.1007/s10637-018-0645-2

By:

Weldon Gilcrease, G.;
Stenehjem, David D.;
Wade, Mark L.;
Weis, John;
McGregor, Kimberly;
Whisenant, Jonathan;
Boucher, Kenneth M.;
Thorne, Kelli;
Orgain, Nicole;
Garrido-Laguna, Ignacio;
Sharma, Sunil

Publication type:

Article

Induction of endoplasmic reticulum stress by aminosteroid derivative RM-581 leads to tumor regression in PANC-1 xenograft model.

Published in:

Investigational New Drugs, 2019, v. 37, n. 3, p. 431, doi. 10.1007/s10637-018-0643-4

By:

Perreault, Martin;
Maltais, René;
Roy, Jenny;
Picard, Sylvain;
Popa, Ion;
Bertrand, Nicolas;
Poirier, Donald

Publication type:

Article

Combination treatment of cancer cells with pan-Akt and pan-mTOR inhibitors: effects on cell cycle distribution, p-Akt expression level and radiolabelled-choline incorporation.

Published in:

Investigational New Drugs, 2019, v. 37, n. 3, p. 424, doi. 10.1007/s10637-018-0642-5

By:

Phyu, Su Myat;
Smith, Tim A. D.

Publication type:

Article

Chemosensitivity of various peritoneal cancer cell lines to HIPEC and PIPAC: comparison of an experimental duplex drug to standard drug regimens in vitro.

Published in:

Investigational New Drugs, 2019, v. 37, n. 3, p. 415, doi. 10.1007/s10637-018-0641-6

By:

Weinreich, Jürgen;
Struller, Florian;
Sautkin, Iaroslav;
Giuashvili, Shalva;
Reymond, Marc;
Königsrainer, Alfred;
Schott, Timm C.

Publication type:

Article

Hand-foot-skin reaction of grade ≥ 2 within sixty days as the optimal clinical marker best help predict survival in sorafenib therapy for HCC.

Published in:

Investigational New Drugs, 2019, v. 37, n. 3, p. 401, doi. 10.1007/s10637-018-0640-7

By:

Wang, Enxin;
Xia, Dongdong;
Bai, Wei;
Wang, Zhexuan;
Wang, Qiuhe;
Liu, Lei;
Wang, Wenjun;
Yuan, Jie;
Li, Xiaomei;
Chen, Hui;
Lv, Yong;
Niu, Jing;
He, Chuangye;
Guo, Wengang;
Yin, Zhanxin;
Luo, Bohan;
Han, Na;
Wang, Zhengyu;
Yu, Tianlei;
Yuan, Xulong

Publication type:

Article

A natural compound derivative P-13 inhibits STAT3 signaling by covalently inhibiting Janus kinase 2.

Published in:

Investigational New Drugs, 2019, v. 37, n. 3, p. 452, doi. 10.1007/s10637-018-0637-2

By:

Huang, Hui;
Niu, Junxing;
Wang, Fei;
Hu, Lihong;
Yu, Qiang

Publication type:

Article